Cargando…

CpG ODN1826 as a Promising Mucin1-Maltose-Binding Protein Vaccine Adjuvant Induced DC Maturation and Enhanced Antitumor Immunity

Mucin 1 (MUC1), being an oncogene, is an attractive target in tumor immunotherapy. Maltose binding protein (MBP) is a potent built-in adjuvant to enhance protein immunogenicity. Thus, a recombinant MUC1 and MBP antitumor vaccine (M-M) was constructed in our laboratory. To enhance the antitumor immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Jie, Jing, Zhang, Yixin, Zhou, Hongyue, Zhai, Xiaoyu, Zhang, Nannan, Yuan, Hongyan, Ni, Weihua, Tai, Guixiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877781/
https://www.ncbi.nlm.nih.gov/pubmed/29558459
http://dx.doi.org/10.3390/ijms19030920
_version_ 1783310772229636096
author Jie, Jing
Zhang, Yixin
Zhou, Hongyue
Zhai, Xiaoyu
Zhang, Nannan
Yuan, Hongyan
Ni, Weihua
Tai, Guixiang
author_facet Jie, Jing
Zhang, Yixin
Zhou, Hongyue
Zhai, Xiaoyu
Zhang, Nannan
Yuan, Hongyan
Ni, Weihua
Tai, Guixiang
author_sort Jie, Jing
collection PubMed
description Mucin 1 (MUC1), being an oncogene, is an attractive target in tumor immunotherapy. Maltose binding protein (MBP) is a potent built-in adjuvant to enhance protein immunogenicity. Thus, a recombinant MUC1 and MBP antitumor vaccine (M-M) was constructed in our laboratory. To enhance the antitumor immune activity of M-M, CpG oligodeoxynucleotides 1826 (CpG 1826), a toll-like receptor-9 agonist, was examined in this study as an adjuvant. The combination of M-M and CpG 1826 significantly inhibited MUC1-expressing B16 cell growth and prolonged the survival of tumor-bearing mice. It induced MUC1-specific antibodies and Th1 immune responses, as well as the Cytotoxic T Lymphocytes (CTL) cytotoxicity in vivo. Further studies showed that it promoted the maturation and activation of the dendritic cell (DC) and skewed towards Th1 phenotype in vitro. Thus, our study revealed that CpG 1826 is an efficient adjuvant, laying a foundation for further M-M clinical research.
format Online
Article
Text
id pubmed-5877781
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-58777812018-04-09 CpG ODN1826 as a Promising Mucin1-Maltose-Binding Protein Vaccine Adjuvant Induced DC Maturation and Enhanced Antitumor Immunity Jie, Jing Zhang, Yixin Zhou, Hongyue Zhai, Xiaoyu Zhang, Nannan Yuan, Hongyan Ni, Weihua Tai, Guixiang Int J Mol Sci Article Mucin 1 (MUC1), being an oncogene, is an attractive target in tumor immunotherapy. Maltose binding protein (MBP) is a potent built-in adjuvant to enhance protein immunogenicity. Thus, a recombinant MUC1 and MBP antitumor vaccine (M-M) was constructed in our laboratory. To enhance the antitumor immune activity of M-M, CpG oligodeoxynucleotides 1826 (CpG 1826), a toll-like receptor-9 agonist, was examined in this study as an adjuvant. The combination of M-M and CpG 1826 significantly inhibited MUC1-expressing B16 cell growth and prolonged the survival of tumor-bearing mice. It induced MUC1-specific antibodies and Th1 immune responses, as well as the Cytotoxic T Lymphocytes (CTL) cytotoxicity in vivo. Further studies showed that it promoted the maturation and activation of the dendritic cell (DC) and skewed towards Th1 phenotype in vitro. Thus, our study revealed that CpG 1826 is an efficient adjuvant, laying a foundation for further M-M clinical research. MDPI 2018-03-20 /pmc/articles/PMC5877781/ /pubmed/29558459 http://dx.doi.org/10.3390/ijms19030920 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jie, Jing
Zhang, Yixin
Zhou, Hongyue
Zhai, Xiaoyu
Zhang, Nannan
Yuan, Hongyan
Ni, Weihua
Tai, Guixiang
CpG ODN1826 as a Promising Mucin1-Maltose-Binding Protein Vaccine Adjuvant Induced DC Maturation and Enhanced Antitumor Immunity
title CpG ODN1826 as a Promising Mucin1-Maltose-Binding Protein Vaccine Adjuvant Induced DC Maturation and Enhanced Antitumor Immunity
title_full CpG ODN1826 as a Promising Mucin1-Maltose-Binding Protein Vaccine Adjuvant Induced DC Maturation and Enhanced Antitumor Immunity
title_fullStr CpG ODN1826 as a Promising Mucin1-Maltose-Binding Protein Vaccine Adjuvant Induced DC Maturation and Enhanced Antitumor Immunity
title_full_unstemmed CpG ODN1826 as a Promising Mucin1-Maltose-Binding Protein Vaccine Adjuvant Induced DC Maturation and Enhanced Antitumor Immunity
title_short CpG ODN1826 as a Promising Mucin1-Maltose-Binding Protein Vaccine Adjuvant Induced DC Maturation and Enhanced Antitumor Immunity
title_sort cpg odn1826 as a promising mucin1-maltose-binding protein vaccine adjuvant induced dc maturation and enhanced antitumor immunity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877781/
https://www.ncbi.nlm.nih.gov/pubmed/29558459
http://dx.doi.org/10.3390/ijms19030920
work_keys_str_mv AT jiejing cpgodn1826asapromisingmucin1maltosebindingproteinvaccineadjuvantinduceddcmaturationandenhancedantitumorimmunity
AT zhangyixin cpgodn1826asapromisingmucin1maltosebindingproteinvaccineadjuvantinduceddcmaturationandenhancedantitumorimmunity
AT zhouhongyue cpgodn1826asapromisingmucin1maltosebindingproteinvaccineadjuvantinduceddcmaturationandenhancedantitumorimmunity
AT zhaixiaoyu cpgodn1826asapromisingmucin1maltosebindingproteinvaccineadjuvantinduceddcmaturationandenhancedantitumorimmunity
AT zhangnannan cpgodn1826asapromisingmucin1maltosebindingproteinvaccineadjuvantinduceddcmaturationandenhancedantitumorimmunity
AT yuanhongyan cpgodn1826asapromisingmucin1maltosebindingproteinvaccineadjuvantinduceddcmaturationandenhancedantitumorimmunity
AT niweihua cpgodn1826asapromisingmucin1maltosebindingproteinvaccineadjuvantinduceddcmaturationandenhancedantitumorimmunity
AT taiguixiang cpgodn1826asapromisingmucin1maltosebindingproteinvaccineadjuvantinduceddcmaturationandenhancedantitumorimmunity